| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3275385 | Médecine des Maladies Métaboliques | 2011 | 8 Pages |
Abstract
Further comparative studies are needed to evaluate the impact of weight and metabolic status of patients as well as other decision criteria (duration of diabetes, patient's age, etc.) on the risk/benefit ratio of treatment based on GLP-1 analogs or insulin. These new data, plus the cost of treatment will allow a better understanding of patient profiles and their responses to treatment, with the objective to help prescribers to better customize the treatment of T2DM patients after failure of oral treatments.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
B. Guerci, S. Halimi, P. Gourdy, E. Disse,